Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

Purpose

Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.

Conditions

  • SARS-CoV-2
  • Covid19

Eligibility

Eligible Ages
Over 1 Year
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Nasopharyngeal swab collected for SARS-CoV-2 RT-PCR with EUA as per standard of care within 3 hours of CoviDx Rapid Antigen Swab collection - First onset of COVID-19-like symptoms within the last 5 days - ≥ 1 year of age - Signed Informed Consent

Exclusion Criteria

  • Unable or unwilling to provide signed, Informed Consent - Less than 1 year of age - SARS-Cov-2 RT-PCR collection that occurred > 3 hours from CoviDx Rapid Antigen Swab collection - First onset of COVID-19-like symptoms occurring more than 5 days from study visit - Invalid or missing PCR test results - Use of a non-high-sensitive SARS-CoV-2 test as the qualifying SARS-CoV-2 RT-PCR test (e.g., Abbott ID NOW, rapid antigen tests, tests that do not have FDA EUA, a test that was not approved by Sponsor for use in the study) - Enrollment in another study involving the collection of a nasopharyngeal or nasal swab - Receipt of a COVID-19 vaccine or participation in a COVID-19 vaccine study

Study Design

Phase
Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
  • Device: POC CoviDx™ Rapid Antigen Test
    All patients will have a nasal swab for CoviDx™ Rapid Antigen testing

Recruiting Locations

More Details

NCT ID
NCT04750629
Status
Completed
Sponsor
Lumos Diagnostics

Detailed Description

All patients who present with Covid-19-like symptoms within 5 days prior to consult, who consent to participate in the study, will undergo a nasopharyngeal swab (NP) collected for SARS-CoV-2 RT-PCR with EUA as per standard of care and nasal swab collection for CoviDx Rapid Antigen testing.